Pediatrics - Allergy and Immunology
Experts recommend Covid jabs for some under-18s in UK – “advice is that 16 to 18-year-olds can be offered a Pfizer jab if they are in a priority group or live with someone who has a weakened immune system”.
20 Jul, 2021 | 10:15h | UTCCommentaries: Experts recommend Covid jabs for some under-18s in UK – BBC
New Zealand children falling ill in high numbers due to Covid ‘immunity debt’.
14 Jul, 2021 | 11:16h | UTCNew Zealand children falling ill in high numbers due to Covid ‘immunity debt’ – The Guardian
Related: New Zealand, where Covid-19 is dormant, fights another respiratory virus – The New York Times
CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.
24 Jun, 2021 | 09:51h | UTCSee also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.
18 Jun, 2021 | 08:36h | UTCTreatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine
Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
18 Jun, 2021 | 08:35h | UTCEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.
18 Jun, 2021 | 08:33h | UTCAudio Interview: Covid-19 in Children – New England Journal of Medicine
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.
14 Jun, 2021 | 08:48h | UTCCommentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay
Commentary on Twitter
About 1 in every 3,000 children who got COVID ended up with MIS-C. MIS-C incidence among Black persons and Hispanic or Latino persons was approximately 9x higher, and incidence among Asian or Pacific Islander persons was approximately 3x higher https://t.co/JTEsvgvFcz
— Daniel Griffin MD PhD (@DanielGriffinMD) June 12, 2021
Synopsis | Updates to the Pediatrics Asthma Management Guidelines.
8 Jun, 2021 | 09:22h | UTCUpdates to the Pediatrics Asthma Management Guidelines – JAMA Pediatrics (free for a limited period)
Original Guideline: 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group
Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.
3 Jun, 2021 | 11:06h | UTCCommentary: Most severe effects of MIS-C in children typically resolve within six months, new research suggests – CNN AND Children who developed a rare inflammation disease after COVID-19 are mostly better after 6 months, but some still suffer fatigue and anxiety, a small UK study found – Insider AND Most severe effects of PIMS-TS resolved at six months – HealthDay
Commentary on Twitter
New Research—A study of 46 patients with #PIMSTS found that most symptoms were resolved after 6 months, but fatigue, difficulty exercising, and emotional difficulties persisted in some childrenhttps://t.co/mHz3D8a11d #COVID19 @GreatOrmondSt @KarynMoshal pic.twitter.com/PJCxGGmJNo
— The Lancet Child & Adolescent Health (@LancetChildAdol) May 24, 2021
ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.
20 May, 2021 | 08:21h | UTC
Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.
14 May, 2021 | 08:23h | UTC
RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.
14 May, 2021 | 08:25h | UTCCommentary: New drug shows promise against tough-to-manage asthma – MedicalXpress
RCT: Tympanostomy-tube placement does not reduce episodes of acute otitis media among children 6 to 35 months of age with recurrent acute otitis media
13 May, 2021 | 05:57h | UTCCommentary: No lasting benefit to tubes over antibiotics for childhood ear infections – University of Pittsburgh
Practice Guideline: Prevention and management of allergic reactions to food in child care centers and schools
11 May, 2021 | 09:06h | UTC
Commentary on Twitter (thread – click for more)
Many clickbait headlines are misrepresenting new guidelines on managing #foodallergy in schools.
This is a nuanced topic and these guidelines evaluated all available evidence surrounding reactions in the school setting.
Access here: https://t.co/RIhfAmTSVd
My thoughts 🧵⬇️
— Dr. Dave Stukus (@AllergyKidsDoc) May 7, 2021
Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease
22 Apr, 2021 | 08:40h | UTC
Commentaries on Twitter
Early data from @RCHMelbourne show that, at 3-6 month follow-up, all 151 children with mild and asymptomatic #COVID19 had returned to their baseline health status and post-acute COVID-19 symptoms had resolved.
Letter from @Shidan_Tosif & colleagues: https://t.co/XXa0EPIgPY
— The Lancet Child & Adolescent Health (@LancetChildAdol) April 20, 2021
Given such little available data, this study from Australia on post-acute COVID-19 symptoms in children is very important
Findings are extremely reassuring
Post-acute symptoms were rare, and mild (cough 4%, fatigue 2%, cough and fatigue 1%)
Great news!https://t.co/TEJyES3Crx
— Alasdair Munro (@apsmunro) April 21, 2021
Great to see research looking at whether long Covid is a problem in children.
From this Melbourne cohort, enduring cough and fatigue are uncommon.
It hasn’t been clear to me whether borders will reopen before children are vaccinated so this is VIP https://t.co/iLXqwXJmOt
— Jin Russell (@DrJinRussell) April 21, 2021
Truly encouraging data on post-acute #COVID19 in children. Single-center in Australia. n=151.
8% post-acute symptoms – all symptomatic COVID-19.
Mild symptoms: cough 4%, fatigue 2%, both 1%. Duration: cough 3-8w; post-viral fatigue 6-8w. All solved in follow-up time 3-6 months. https://t.co/vKrEFZlw3C— Dr Pablo Guisado Vasco MD, PhD (@PabloGVasco) April 21, 2021
[Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents
1 Apr, 2021 | 03:52h | UTCPress release: Pfizer-BioNTech Announce Positive Topline Results Of Pivotal Covid-19 Vaccine Study In Adolescents
Commentaries: The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents – The New York Times AND Covid: Children ‘well protected by Pfizer vaccine’ – BBC AND Pfizer Says COVID-19 Vaccine Shows ‘100% Efficacy’ In Adolescents – NPR AND Pfizer says its COVID-19 vaccine protects younger teens – Associated Press AND Pfizer and BioNTech say vaccine prevents Covid-19 in adolescents – STAT
Commentaries on Twitter
Press release for BNT-Pfizer vaccine efficacy in 2,260 adolescents aged 12 to 15: 0 Covid-19 among vaccinated, 18 in placebo group. Adverse reactions similar to those in 16 to 25 year-olds (no extra data: could be quite high, so eyes on that) https://t.co/mCoLmCtpgv
— Hilda Bastian, PhD (@hildabast) March 31, 2021
This is really terrific
In trial of 2260 adolescents 12-15 year of age, Pfizer vaccine highly effective at preventing infections
18 infections in placebo group
0 infections in vaccine group
Robust antibody response
No serious side-effects
Looking forward to @US_FDA review https://t.co/VymGXOVb5E
— Ashish K. Jha, MD, MPH (@ashishkjha) March 31, 2021
Clinician Guide to COVID-19 diagnostics in children
21 Mar, 2021 | 21:48h | UTCClinician guide to COVID-19 diagnostics – ADC Education & Practice
Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)
23 Feb, 2021 | 01:57h | UTC
A food allergy epidemic… or just another case of overdiagnosis?
19 Feb, 2021 | 02:13h | UTCA food allergy epidemic… or just another case of overdiagnosis? – The BMJ Opinion
Original study: Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 – The BMJ
Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children
3 Feb, 2021 | 01:39h | UTC
Commentaries on Twitter
In this cohort study, treatment w IVIG + methylprednisolone was associated w lower risk of treatment failure (defined as fever persistence 2d after start of therapy or fever recrudescence within 7 days) vs IVIG alone among children w MIS-C https://t.co/LjEBFuf33q
— JAMA (@JAMA_current) February 1, 2021
Yes, retrospective, but I find these data interesting as I expect the combined treatment group to be the sicker of the 2
Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C https://t.co/Oio8t05zQ1 via @JAMA_current @JAMANetwork
— Joshua Denson MD (@jdensonMD) February 2, 2021